Link Barbara, Torres Crigna Adriana, Hölzel Michael, Giordano Frank A, Golubnitschaja Olga
Department of Radiation Oncology, University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, 53127 Bonn, Germany.
Institute of Experimental Oncology, University Hospital Bonn, Rheinische Friedrich-Wilhelms-Universität Bonn, 53127 Bonn, Germany.
J Clin Med. 2021 Oct 31;10(21):5124. doi: 10.3390/jcm10215124.
Patients with metastatic cancers often require radiotherapy (RT) as a palliative therapy for cancer pain. RT can, however, also induce systemic antitumor effects outside of the irradiated field (abscopal effects) in various cancer entities. The occurrence of the abscopal effect is associated with a specific immunological activation in response to RT-induced cell death, which is mainly seen under concomitant immune checkpoint blockade. Even if the number of reported apscopal effects has increased since the introduction of immune checkpoint inhibition, its occurrence is still considered rare and unpredictable. The cases reported so far may nevertheless allow for identifying first biomarkers and clinical patterns. We here review biomarkers that may be helpful to predict the occurrence of abscopal effects and hence to optimize therapy for patients with metastatic cancers.
转移性癌症患者通常需要放疗(RT)作为缓解癌痛的姑息治疗方法。然而,放疗也可在各种癌症实体中诱导照射野以外的全身抗肿瘤效应(远隔效应)。远隔效应的发生与放疗诱导的细胞死亡所引发的特定免疫激活有关,这主要见于同时进行免疫检查点阻断的情况下。尽管自引入免疫检查点抑制以来,报告的远隔效应数量有所增加,但其发生仍被认为罕见且不可预测。然而,迄今为止报告的病例可能有助于识别首批生物标志物和临床模式。我们在此回顾可能有助于预测远隔效应发生从而优化转移性癌症患者治疗的生物标志物。